When.com Web Search

  1. Ads

    related to: egfr negative lung cancer treatment breakthrough

Search results

  1. Results From The WOW.Com Content Network
  2. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    Treatment of adults with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2]

  3. Erlotinib - Wikipedia

    en.wikipedia.org/wiki/Erlotinib

    Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. [4] Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body. [4]

  4. Epidermal growth factor receptor - Wikipedia

    en.wikipedia.org/wiki/Epidermal_growth_factor...

    CimaVax-EGF, an active vaccine targeting EGF as the major ligand of EGF, uses a different approach, raising antibodies against EGF itself, thereby denying EGFR-dependent cancers of a proliferative stimulus; [34] it is in use as a cancer therapy against non-small-cell lung carcinoma (the most common form of lung cancer) in Cuba, and is ...

  5. Cancer breakthrough as groundbreaking trials see seriously ...

    www.aol.com/groundbreaking-cancer-trials-see...

    Dr Searle added: “These drugs are a huge breakthrough in this type of cancer, allowing patients without standard treatment options to achieve remission, in many cases for months or years.

  6. Gefitinib - Wikipedia

    en.wikipedia.org/wiki/Gefitinib

    A pre-planned sub-group analyses showed that progression-free survival (PFS) was significantly longer for gefitinib than chemotherapy in patients with EGFR mutation positive tumours (HR 0.48, 95 per cent CI 0.36 to 0.64, p less than 0.0001), and significantly longer for chemotherapy than gefitinib in patients with EGFR mutation negative tumours ...

  7. Repotrectinib - Wikipedia

    en.wikipedia.org/wiki/Repotrectinib

    Repotrectinib is indicated for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. [1] [4]In June 2024, the US Food and Drug Administration (FDA) expanded the indication to include the treatment of people twelve years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or ...

  1. Ads

    related to: egfr negative lung cancer treatment breakthrough